Metformin treatment after the hypoxia-ischemia attenuates brain injury in newborn rats

Oncotarget. 2017 Sep 8;8(43):75308-75325. doi: 10.18632/oncotarget.20779. eCollection 2017 Sep 26.

Abstract

Neonatal hypoxic-ischemic (HI) brain injury is a devastating disease that often leads to death and detrimental neurological deficits. The present study was designed to evaluate the ability of metformin to provide neuroprotection in a model of neonatal hypoxic-ischemic brain injury and to study the associated molecular mechanisms behind these protective effects. Here, we found that metformin treatment remarkably attenuated brain infarct volumes and brain edema at 24 h after HI injury, and the neuroprotection of metformin was associated with inhibition of neuronal apoptosis, suppression of the neuroinflammation and amelioration of the blood brain barrier breakdown. Additionally, metformin treatment conferred long-term protective against brain damage at 7 d after HI injury. Our study indicates that metformin treatment protects against neonatal hypoxic-ischemic brain injury and thus has potential as a therapy for this disease.

Keywords: blood-brain barrier; metformin; neonatal hypoxic-ischemic brain injury; neuroinflammation; neuronal apoptosis.